Yazar "Keser Emiroglu M." seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim Yok
    Öğe
    Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008–2014
    (Taylor and Francis Inc., 2016) Ceyhan M.; Ozsurekci Y.; Gürler N.; Öksüz L.; Aydemir S.; Ozkan S.; Yuksekkaya S.; Keser Emiroglu M.; Gültekin M.; Yaman A.; Kiremitci A.; Yanık K.; Karli A.; Ozcinar H.; Aydin F.; Bayramoglu G.; Zer Y.; Gulay Z.; Gayyurhan E.D.; Gül M.; Özakın C.; Güdücüoğlu H.; Perçin D.; Akpolat N.; Ozturk C.; Camcıoğlu Y.; Karadağ Öncel E.; Çelik M.; Şanal L.; Uslu H.
    Successful vaccination policies for protection from invasive pneumococcal diseases (IPD) dependent on determination of the exact serotype distribution in each country. We aimed to identify serotypes of pneumococcal strains causing IPD in children in Turkey and emphasize the change in the serotypes before and after vaccination with 7-valent pneumococcal conjugate vaccine (PCV-7) was included and PCV-13 was newly changed in Turkish National Immunization Program. Streptococcus pneumoniae strains were isolated at 22 different hospitals of Turkey, which provide healthcare services to approximately 65% of the Turkish population. Of the 335 diagnosed cases with S. pneumoniae over the whole period of 2008–2014, the most common vaccine serotypes were 19F (15.8%), 6B (5.9%), 14 (5.9%), and 3 (5.9%). During the first 5 y of age, which is the target population for vaccination, the potential serotype coverage ranged from 57.5 % to 36.8%, from 65.0% to 44.7%, and from 77.4% to 60.5% for PCV-7, PCV-10, and PCV-13 in 2008–2014, respectively. The ratio of non-vaccine serotypes was 27.2% in 2008–2010 whereas was 37.6% in 2011–2014 (p=0.045). S. penumoniae serotypes was less non-susceptible to penicillin as compared to our previous results (33.7 vs 16.5 %, p=0.001). The reduction of those serotype coverage in years may be attributed to increasing vaccinated children in Turkey and the increasing non-vaccine serotype may be explained by serotype replacement. Our ongoing IPD surveillance is a significant source of information for the decision-making processes on pneumococcal vaccination. © 2016 Taylor & Francis Group, LLC.